Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT103 in Glucocorticoid-induced Osteoporosis
CTR20221227Phase 2Terminated
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of narlumosbart in glucocorticoid-induced osteoporosis (GIOP), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started May 2022; status: terminated.
02
Drugs
narlumosbart
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on CTR20221227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221227.